证券代码：600513 证券简称：联环药业 公告编号：2025—054 江苏联环药业股份有限公司 股票交易异常波动的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 日、8 月 4 日、8 月 5 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。 控股股东及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资 产重组、股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业 务合作、引进战略投资者等重大事项。 -4,500.00 万 元 人 民 币 至 -3,800.00 万 元 人 民 币 ， 与 上 年 同 期 相 比 将 减 少 一、股票交易异常波动的具体情况 公司股票于 2025 年 8 月 1 日、8 月 4 日、8 月 5 日连续三个交易日内收盘价 格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属 于股票交易异常波动。 （一）生产经营情况 经公司自查，公司目前生产经营正常，市场环境、行业 ...

Group 1 - The State Council issued opinions on gradually promoting free preschool education, starting from the autumn semester of 2025, exempting public kindergarten tuition fees for children in their last year [2] - The People's Bank of China and seven departments released guidelines to support new industrialization, focusing on enhancing financial services for emerging industries and promoting multi-level capital market financing [3] - The National Health Commission and 16 departments launched the "Healthy China Action - Healthy Environment Promotion Action Implementation Plan (2025-2030)" to advance the construction of a beautiful and healthy China [3] Group 2 - In July, the China Logistics and Purchasing Federation reported a logistics industry prosperity index of 50.5%, indicating continued expansion in logistics demand despite adverse weather conditions [4] - The China Electromechanical Products Import and Export Chamber opposed unfair competition in the photovoltaic industry, particularly regarding exports below cost [4] - The Shanghai Development and Reform Commission announced that all new energy power generation will participate in market trading by the end of 2025, impacting pricing mechanisms [4] Group 3 - A-share company Upwind New Materials may apply for a continuous suspension of trading if stock prices rise further [6] - Dongjie Intelligent reported no significant changes in production and operations [6] - Muyuan Foods reported a revenue of 11.639 billion yuan from pig sales in July, a year-on-year decrease of 10.41% [6] - Vanke A received a loan of up to 1.681 billion yuan from Shenzhen Metro Group [6] - Ruoyuchen plans to issue H-shares and list on the Hong Kong Stock Exchange [6] - Anker Detection's controlling shareholder changed to Xirui Technology, and the stock resumed trading [6] - Daodaquan's controlling shareholder plans to increase its stake by 50 million to 100 million yuan [6] - Sanjiang Shopping will not renew its cooperation agreement with Hema Fresh after it expires [6] - Yinglian Co. signed a strategic cooperation agreement with a well-known cylindrical battery company [6] - Lianhuan Pharmaceutical's LH-1801 project is not expected to significantly impact revenue and operating performance in the near term [6]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced an abnormal fluctuation in its stock trading, with a cumulative price increase deviation of over 20% in three consecutive trading days [1] - The LH-1801 project is currently in the research and development stage and is not expected to have a significant impact on the company's revenue and operating performance in the foreseeable future [1]

江苏联环药业股份有限公司 江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 2025 年第一次临时股东会会议资料 （股票代码：600513） 会议日期：二〇二五年八月十一日 - 1 - 江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 目 录 | 股东会会议须知··························································- – | | 3 | | --- | --- | --- | | 联环药业 年第一次临时股东会会议基本情况及议程·······················- 4 - | 2025 | | | 2025 年第一次临时股东会投票卡···········································- 6 - | | | | 议案一：《关于选举吴方女士为公司独立董事的议案》··························- 7 - | | | | 议案二：《关于公司拟发行科技创新债券的议案》······························- 8 - | | | - 2 - 江苏 ...

Group 1: Pharmaceutical Regulations - Starting from August 1, all retail pharmacies in Foshan will implement a real-name registration system for the sale of 47 key controlled drugs, primarily for treating symptoms of Chikungunya fever [1] - The list of controlled drugs includes common medications such as Ibuprofen, Compound Cold Medicine, and Lianhua Qingwen capsules [1] Group 2: Clinical Trials and Drug Approvals - Kangning Jereh's innovative drug JSKN022, a PD-L1/αvβ6 dual-specific antibody drug conjugate, has received acceptance for clinical trial application from the National Medical Products Administration [3] - Yipin Hong's innovative drug APH03621 for endometriosis treatment has also received clinical trial registration acceptance from the National Medical Products Administration [5] - Lianhua Pharmaceutical's subsidiary has passed the consistency evaluation for the generic drug Lincomycin Hydrochloride Injection [4] Group 3: Financial Performance - China Resources Medical expects a profit decline of 20% to 25% for the first half of the year, with a significant drop of 55% to 60% when excluding one-time gains [6] - Zhenghai Bio reported a net profit of 46.49 million yuan for the first half of 2025, a decrease of 45.97% year-on-year, with revenue of 188 million yuan, down 5.14% [8] Group 4: Corporate Actions - Kexing Bio has spent 47.38 million yuan to repurchase 1.27 million shares, representing 0.63% of its total share capital [8] - WuXi AppTec has repurchased 6.51 million A-shares for a total of 497 million yuan [10] - Tian Tan Bio has decided to abandon the acquisition opportunity of Pailin Bio due to potential competition with its core business [9] Group 5: Industry Developments - Significant progress has been made in HIV vaccine research in China, with the completion of the first phase clinical trial for a replicating Tian Tan smallpox vaccine carrier HIV vaccine [11][13] - Sanofi announced the discontinuation of its PCSK9 inhibitor drug Alirocumab in China due to global supply issues and a strategic shift in its cardiovascular product line [12]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the quality and efficacy of Lincomycin Hydrochloride Injection, which is expected to enhance the product's market share and competitiveness [1][3]. Drug Basic Information - Drug Name: Lincomycin Hydrochloride Injection - Dosage Form: Injection - Registration Classification: Chemical Drug - Specification: 2ml:0.6g - Original Drug Approval Number: Guoyao Zhunzi H41020229 - Drug Registration Standard Number: YBH18522025 - Acceptance Number: CYHB2450458 - Approval Conclusion: The product has passed the consistency evaluation for quality and efficacy [1]. Market Impact - The sales revenue for Lincomycin Hydrochloride Injection (2ml:0.6g) in domestic sample hospitals for 2024 is reported to be 10.82 million yuan [1]. - The successful consistency evaluation is anticipated to expand the market share of the drug, although it is noted that the approval is not expected to have a significant impact on the company's recent operating performance [3]. R&D Investment - As of the date of the announcement, the R&D investment for the consistency evaluation of Lincomycin Hydrochloride Injection by Changle Pharmaceutical is approximately in RMB [2]. - In 2025, Changle Pharmaceutical has obtained 2 production licenses [2].

Core Viewpoint - The announcement highlights that the company's subsidiary, Changle Pharmaceutical, has successfully passed the consistency evaluation for the quality and efficacy of Lincomycin Hydrochloride Injection, indicating a significant milestone in its product development and market potential [1] Group 1: Product Development - Changle Pharmaceutical's Lincomycin Hydrochloride Injection (specification: 2ml:0.6g) is classified as a lincosamide antibiotic, suitable for treating respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] - In 2025, Changle Pharmaceutical received two production approvals for its products, reflecting its ongoing commitment to expanding its pharmaceutical offerings [1] Group 2: Financial Performance - The research and development investment for the consistency evaluation of Lincomycin Hydrochloride Injection amounted to approximately 2.328 million yuan [1] - In 2024, the domestic sales revenue for Lincomycin Hydrochloride Injection in sample hospitals reached 10.8176 million yuan, indicating a strong market presence and demand for the product [1]

证券代码：600513 证券简称：联环药业 公告编号：2025—053 江苏联环药业股份有限公司 关于控股子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注册分类：化学药品 规格：2ml:0.6g 原药品批准文号：国药准字 H41020229 药品注册标准编号：YBH18522025 受理号：CYHB2450458 通知书编号：2025B03431 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。 二、药品的其他情况 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡常乐制药 有限责任公司（以下简称"常乐制药"）于近日收到国家药品监督管理局核准签 发的关于盐酸林可霉素注射液（以下简称"本品"）《药品补充申请批准通知 书》，批准常乐制药本品通过仿制药质量和疗效一致性评价（以下简称"一致性 评价"）。现将相关情况公告如下： 一、药品基本信息 药品名称：盐酸林可霉素注射液 剂型：注射剂 截至本公告披露日，2025 年常乐制药共获得 2 个生产批件。 三、对公司的影响及风险提示 公司 ...

Core Viewpoint - The company, Lianhuan Pharmaceutical, announced that its subsidiary, Xinxiang Changle Pharmaceutical, received approval from the National Medical Products Administration for the supplement application of Lincomycin Hydrochloride Injection, indicating successful consistency evaluation of the generic drug [1] Group 1: Company Developments - Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical, has been approved for Lincomycin Hydrochloride Injection, which is a significant milestone for the company [1] - The approved product is a Lincomycin class antibiotic, indicated for respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] Group 2: Market Insights - The sales revenue for Lincomycin Hydrochloride Injection (2ml:0.6g) in domestic sample hospitals is projected to be 10.82 million yuan in 2024 [1]

Group 1 - Company Lianhuan Pharmaceutical (600513.SH) announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of Lincomycin Hydrochloride Injection [1] - The approved product, Lincomycin Hydrochloride Injection (specification: 2ml:0.6g), is classified as a lincosamide antibiotic, indicated for respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] - According to the MoSheng Medical Database, the sales revenue of Lincomycin Hydrochloride Injection (specification: 2ml:0.6g) in domestic sample hospitals is projected to be 10.82 million yuan in 2024 [1]